RNS Number : 4440K IQ-AI Limited 05 May 2022 5 May 2022 IQ-AI Ltd (“IQ-AI” or the “Company”) Notice of AGM IQ-AI Limited announces that notice of the annual general meeting of the Company, to be held at Third Floor, Forum 4, Grenville Street, St Helier, Jersey, JE2 4UF on 30
RNS Number : 7683J IQ-AI Limited 28 April 2022 28 April 2022 IQ-AI Ltd (“IQ-AI”, the “Company” and, together with its subsidiaries, the “Group”) Publication of Annual Report The Board of IQ-AI Ltd are pleased to present announce that the Company’s audited financial statements for the year ended 31 December 2021.
RNS Number : 2319E IQ-AI Limited 09 March 2022 FOR IMMEDIATE RELEASE IQ-AI LIMITED (“IQ-AI” or the “Company”) IQAI’s Sponsored Phase I Clinical Trial is Open Milwaukee – 9 March 2022: IQ-AI Limited (OTCQB: IQAIF) (LSE: IQAI) is pleased to announce that the sponsored Phase I clinical trial for oral gallium maltolate (GaM) is
RNS Number : 0358D IQ-AI Limited 28 February 2022 28 February 2022 IQ-AI Ltd (“IQ-AI” or the “Company”) Total Voting Rights In accordance with the Financial Conduct Authority’s Disclosure and Transparency Rules, IQ-AI announces that the Company has 182,621,390 ordinary shares of 1p each in issue, none of which are held in
RNS Number : 9343A IQ-AI Limited 08 February 2022 8 February 2022 IQ-AI Ltd (“IQ-AI” or the “Company”) Issue of shares to Mayo Clinic Further to the Company’s announcement dated 9 November 2020, IQ-AI announces the allotment of 113,781 ordinary shares of 1p each in IQ-AI (the “New Ordinary Shares”) to Mayo
RNS Number : 3367X IQ-AI Limited 04 January 2022 4 January 2022 IQ-AI Ltd (“IQ-AI” or the “Company”) Director/PDMR Shareholding IQ-AI announces that Michael Schmainda, Director of IQAI and CEO of Imaging Biometrics, has been granted an option to subscribe for 5,969,792 ordinary shares of 1p each in the Company (“Ordinary Shares”)
RNS Number : 0182W IQ-AI Limited 17 December 2021 17 December 2021 IQ-AI LIMITED (“IQ-AI” or the “Company”) IQ-AI Prepares for Phase I Clinical Trial Launch IQ-AI Limited (OTCQB: IQAIF) (LSE: IQAI), IQ-AI has been working with the clinical team at the Medical College of Wisconsin (MCW) to qualify a new supplier for encapsulating
RNS Number : 4300V IQ-AI Limited 13 December 2021 13 December 2021 IQ-AI Ltd (“IQ-AI” or the “Company”) Director’s Interest IQ-AI has been advised that Trevor Brown, Chief Executive of the Company, no longer has an interest in Free Association Books Limited. Accordingly, Trevor Brown’s interest in the Company is now 32,203,457
Privacy & Cookies Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.